Anna’s Legacy

Anna Collar was born August 26, 1980 in Powell, Wyoming and grew up in Darrouzett, Texas with her mother, Cathy, father, Randy, and two sisters Brandy and Jennifer. Anna had a passion for life and a smile that lit up any room she entered. Her friends and family remember her as always going out of her way to help others. Anna loved geology and was constantly picking up rocks and other treasures. She made plans to make jewelry out of her treasured stones. She was diagnosed with leukemia on October 14, 2004 and lost her battle on December 22, 2004.

Her dream of a jewelry line remained and is now being fulfilled by her mother, sisters and aunt. A percentage of all sales will go to Anna's Legacy; a group founded in Anna's name that has a desire "to bring joy, laughter, and hope to young people struggling with leukemia," by sending donations to various charities helping children and their families.

Anna's birthstones were Peridot and Carnelian, also the the colors for Leukemia Awareness. After this discovery, we decided to produce a line of jewelry, using these stones for Leukemia Awareness.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap